0.009 -0 (-4.26%) | 12-31 19:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.83 | 1-year : | 1.08 |
Resists | First : | 0.71 | Second : | 0.93 |
Pivot price | 0.46 | |||
Supports | First : | 0.37 | Second : | 0.3 |
MAs | MA(5) : | 0.46 | MA(20) : | 0.5 |
MA(100) : | 0.65 | MA(250) : | 0.65 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 15.7 | D(3) : | 18 |
RSI | RSI(14): 36.2 | |||
52-week | High : | 4.19 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNGX ] has closed above bottom band by 29.2%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.44 - 0.44 | 0.44 - 0.44 |
Low: | 0.38 - 0.39 | 0.39 - 0.39 |
Close: | 0.43 - 0.43 | 0.43 - 0.43 |
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 11 (M) |
Held by Insiders | 1.048e+007 (%) |
Held by Institutions | 0.1 (%) |
Shares Short | 354 (K) |
Shares Short P.Month | 0 (K) |
EPS | -7.69e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -873.3 % |
Return on Assets (ttm) | -40 % |
Return on Equity (ttm) | -23 % |
Qtrly Rev. Growth | 839360 % |
Gross Profit (p.s.) | -17.9 |
Sales Per Share | 423.65 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -9 (M) |
PE Ratio | -0.01 |
PEG Ratio | -0.5 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 3.32 |
Dividend | 0 |
Forward Dividend | 115800 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |